# 4D pharma plc Monotherapy trial approved; the first live biotherapeutic trial in cancer

- Link: https://www.directorstalkinterviews.com/4d-pharma-plc-monotherapy-trial-approved-first-live-biotherapeutic-trial-cancer/412751387
- Published: 2018-05-21T07:16:59+01:00
- Author: Giles Arbor

**4D pharma plc** (LON:DDDD), a pharmaceutical company leading the development of
live biotherapeutics, today announced that the Company has submitted, and the Medicines
and Healthcare products Regulatory Agency (MHRA) has cleared, a Clinical Trial Application
for MRx0518, the Company’s live biotherapeutic for the treatment of cancer. Enrolment
in the Phase 1b study is expected to commence in the second half of 2018.

The first-in-human, two-part Phase Ib study will evaluate the safety, tolerability
and anti-tumour immuno-modulatory effects of MRx0518 in patients with multiple solid
tumour types. Patients enrolled in the study will not have received any previous
cancer therapies and will receive MRx0518 for the period between diagnosis and surgical
resection. In part A of the study, 20 patients will receive MRx0518 open label twice
daily prior to surgery. In part B, up to 100 patients will receive MRx0518 and 20
patients will receive placebo prior to surgery. In addition to assessing safety 
and tolerability, tumour, blood and stool samples will be taken before and after
treatment to investigate the effect of MRx0518 on a range of immunological markers
and the gut microbiome. Survival will also be investigated up to two years post-
surgery.

> **Duncan Peyton, 4D Pharma Plc Chief Executive Officer, commented:** “This groundbreaking
> study is set to be the world’s first live biotherapeutic clinical trial in oncology
> and the first of a number of studies we have planned to investigate MRx0518 in
> multiple cancer settings. The novel design of this trial provides an unrivalled
> opportunity to evaluate the immuno-modulatory properties of MRx0518 and how our
> approach using live biotherapeutics could advance a new approach to the understanding
> of the treatment of cancer.”

Share on:
